Novartis AG believes impressive Phase III long-term efficacy data for Cosentyx (secukinumab) in psoriatic arthritis and ankylosing spondylitis – including impacts on disease progression – will give the interleukin-17A (IL-17A) inhibitor an advantage in a competitive market.
The data were presented during the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting from Nov....







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)